RAD51 and XRCC3 Polymorphisms Are Associated with Increased Risk of Prostate Cancer

Table 1

Clinicopathological characteristics of studied material.

	Parameter
Control group (n=205)
Age
Range	43 - 84
Mean ± SD	63.33 ± 9.28
Median	64
PSAT (ng/ml)
Range	0.004 – 3.94
Mean ± SD	1.09 ± 0.88
Median	0.95
Patients with prostate cancer (n=99)
Age
Range	49 - 85
Mean ± SD	70.38 ± 8.63
Median	71
PSAT (ng/ml)
Range	4.01 – 1489.00
Mean ± SD	59.17 ± 184.59
Median	9.22
Free/total PSA (F/T PSA)
Range	0.04-0.79
Mean ± SD	0.19±0.15
Median	0.16
< 0.16	48
≥ 0.16	51
PSA Density (PSAD, ng/ml)
Range	0.07-56.4
Mean ± SD	2.57±8.44
Median	0.28
< 0.28	49
≥ 0.28	50
Prostate volume (ml)
Range	20.7-191
Mean ± SD	59.5±39.0
Median	48.2
< 48	46
≥ 48	53
Gleason score
< 7	28
≥ 7	71
Cancer stage
T1-T2	58
T3-T4	41